NCT00881894 is a Phase 1 clinical trial of Rotigotine transdermal patch in Healthy, sponsored by UCB Pharma.

Who is sponsoring NCT00881894?

NCT00881894 is sponsored by UCB Pharma.

What drugs are being tested in NCT00881894?

Interventions in NCT00881894: Rotigotine transdermal patch.

Is NCT00881894 still recruiting?

NCT00881894 is currently completed. Last updated 17 October 2014.

Are results published for NCT00881894?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-10-17 · How we verify

NCT00881894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm^2) From 2 Different Manufacturing Processes

Completed Phase 1 Results posted Last updated 17 October 2014

What this trial tests

Phase 1 trial testing Rotigotine transdermal patch in Healthy in 52 participants. Completed in 1 December 2008.

Timeline

1 October 2008

Primary endpoint
1 November 2008

1 December 2008

Quick facts

Lead sponsor	UCB Pharma
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	52
Start date	1 October 2008
Primary completion	1 November 2008
Estimated completion	1 December 2008
Sites	1 location across Germany

Drugs / interventions tested

Rotigotine transdermal patch — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

UCB Pharma — full company profile →

Who can join

Adults 18 to 55, male only, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

AUC(0-tz) of Unconjugated Rotigotine
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application
The AUC(0-tz) is the area under the plasma concentration- time curve from zero up to the last analytically quantifiable concentration.
Cmax of Unconjugated Rotigotine
Time frame: Pharmacokinetic samples were taken predose, after 1, 2, 3, 4, 6, 8, 12, 16, 24 (before patch removal), 25, 26, 28, 30, 32, 36, 40 and 48 hours after patch application.
The Cmax is the maximum plasma concentration.

Sponsor's own description

The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of 2 rotigotine transdermal patches from 2 different manufacturing processes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
Elshoff JP, Timmermann L, Schmid M, Arth C, et al · · 2013 · cited 8× · PMID 24006953 · DOI 10.1185/03007995.2013.841666

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other UCB Pharma trials

Trials by the same sponsor.

NCT01969851 — A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Mo · Phase 2 · completed
NCT01921205 — Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures · Phase 3 · completed
NCT01095393 — National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cim · completed
NCT00350103 — A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy · Phase 3 · completed
NCT00291668 — Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00881894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UCB Pharma
Last refreshed: 17 October 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00881894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing